The Institute for Clinical and Economic Review (ICER) on Thursday released an evidence report assessing the comparative clinical effectiveness and value of emicizumab (Hemlibra, Genentech). The report found that emicizumab offers important improvements in outcomes for people with hemophilia A and inhibitors to Factor VIII, while lowering costs associated with the treatment of this condition.
Emicizumab was approved by the FDA in November of 2017 for prophylaxis (prevention of bleeding) in adults and children who have hemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in those with hemophilia A, and inhibitors interfere with the factor replacement therapy that would typically be used to treat the condition.
This evidence report will be the subject of an upcoming public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) March 29 in Cambridge, Massachusetts. The New England CEPAC is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
To read the full press release, click here.
